269 related articles for article (PubMed ID: 29901215)
1. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
Nicholls SJ
Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
3. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Miyares MA; Davis K
Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
[TBL] [Abstract][Full Text] [Related]
4. Novel HDL-based therapeutic agents.
Joy TR
Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
[TBL] [Abstract][Full Text] [Related]
5. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
Karalis I; Rensen PC; Jukema JW
Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
[No Abstract] [Full Text] [Related]
6. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
Stock J
Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
[No Abstract] [Full Text] [Related]
7. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease.
Holmes MV; Smith GD
Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665
[TBL] [Abstract][Full Text] [Related]
8. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
Catapano AL
Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
[No Abstract] [Full Text] [Related]
9. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Murín J; Pernický M; Kiňová S
Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead--Pro.
Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):439-41. PubMed ID: 26848159
[TBL] [Abstract][Full Text] [Related]
11. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
[TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
13. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
Page MM; Hooper AJ; Burnett JR
Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
[TBL] [Abstract][Full Text] [Related]
14. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targets to raise HDL in patients at risk or with coronary artery disease.
Lüscher TF; von Eckardstein A; Simic B
Curr Vasc Pharmacol; 2012 Nov; 10(6):720-4. PubMed ID: 23259565
[TBL] [Abstract][Full Text] [Related]
16. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
[TBL] [Abstract][Full Text] [Related]
18. HDL and Reverse Cholesterol Transport Biomarkers.
Riggs KA; Rohatgi A
Methodist Debakey Cardiovasc J; 2019; 15(1):39-46. PubMed ID: 31049148
[TBL] [Abstract][Full Text] [Related]
19. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Briand F; Thieblemont Q; Muzotte E; Sulpice T
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
